ID   SH-SY5Y/VCR
AC   CVCL_ZL49
DR   cancercelllines; CVCL_ZL49
DR   Wikidata; Q98132491
RX   PubMed=2566379;
RX   PubMed=3968181;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC   Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0019 ! SH-SY5Y
SX   Female
AG   4Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 05-10-23; Version: 8
//
RX   PubMed=2566379;
RA   Meyers M.B., Rittmann-Grauer L., O'Brien J.P., Safa A.R.;
RT   "Characterization of monoclonal antibodies recognizing a Mr 180,000
RT   P-glycoprotein: differential expression of the Mr 180,000 and Mr
RT   170,000 P-glycoproteins in multidrug-resistant human tumor cells.";
RL   Cancer Res. 49:3209-3214(1989).
//
RX   PubMed=3968181; DOI=10.1083/jcb.100.2.588;
RA   Meyers M.B., Spengler B.A., Chang T.-D., Melera P.W., Biedler J.L.;
RT   "Gene amplification-associated cytogenetic aberrations and protein
RT   changes in vincristine-resistant Chinese hamster, mouse, and human
RT   cells.";
RL   J. Cell Biol. 100:588-597(1985).
//